Mastering the Treatment of Myeloid
Malignancies in the Era of Personalized
Medicine
Targeted Treatment Strategies for AML: Concept of Measurable Residual Disease (MRD) and Management of Treatment-related Adverse Events
Release date: January 22, 2021
Expiration date: January 22, 2023
Estimated Time of Completion: 30 minutes
Description
Cleveland Clinic and Aplastic Anemia & MDS International Foundation present Targeted Treatment Strategies for AML: Concept of Measurable Residual Disease (MRD) and Management of Treatment-related Adverse Events, part of the Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine online series, will provide an in-depth review of myeloproliferative neoplasms, risk stratification, prognostic implications, and treatment options.
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have a relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:
Jeffrey Lancet, MD | ||
Abbvie Pharmaceuticals, Astellas Pharma US, Inc., ElevateBio, Agios Pharmaceuticals, Guidepoint Global | Consulting |
|
Medscape | Teaching and Speaking | |
Daiichi Sankyo, Inc. | Membership on advisory committee or review panels | |
Sudipto Mukherjee, MD, PhD, MPH | ||
Celgene Corporation, a Bristol-Myers Squibb company | Board Membership Consulting Research / Independent Contractor Membership on advisory committee or review panels Research Funding - non-therapeutic investigator trials |
|
Novartis | Consulting Membership on advisory committee or review panels Research Funding |
|
Accerleron Pharma Inc. | Membership on advisory committee or review panels | |
BioPharm | Consulting | |
Bristol-Myers Squibb Co. | Honoraria | |
McGraw Hill | Honoraria - Editor of Hematology Oncology Board Review |
|
Partnership for Health Analytic Research, LLC (PHAR, LLC) | Consulting | |
Bhumika Patel, MD | ||
Alexion | Teaching and Speaking | |
Novartis | Membership on advisory committee or review panels |
Acknowledgment
The Aplastic Anemia and MDS International Foundation and Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of this activity from:
Bristol-Myers Squibb
Geron Corporation
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.